BioSpace News Archive

Swedish Orphan Biovitrum AB announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist, for treatment of immune thrombocytopenia in pediatric patients.

HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells differentiated from adipose tissue-derived stromal cells using Namocell’s Single Cell Dispensers and Takara Bio’s SMART-seq® kits to characterize HepaTx’s novel cell therapies for liver disease.

Well-established Mouse Model Utilizes T-cell-depleted, Mismatched Donor Bone Marrow Transplants in Conjunction with Veto T-cell Transplants to Correct Sickle Cell Disease with Minimal Risk as Reported in Bone Marrow Transplantation ( BMT) Journal

-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- -- Secured $63 million of gross proceeds in an underwritten public offering of common stock for the launch of VAZALORE

- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer (PROC) will be presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Additionally, a trial in progress poster will be presented on an open label Phase 1/2 investigator-sponsored trial of AVB-500

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast

Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known a

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA ® (tivozanib) in Combination with OPDIVO ® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offering of 1,807,143 shares of its common stock, offered at a price of $7.00 to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 271,071

Piezo Motion Corp this week announced the acquisition of Discovery Technology International, Inc., an innovator of standing wave-type piezo technology for rotary and linear motion products